Ocuphire Pharma, Inc.
Quick facts
Phase 3 pipeline
- Low dose pilocarpine · Ophthalmology
Low-dose pilocarpine is a muscarinic acetylcholine receptor agonist that stimulates parasympathetic activity to increase aqueous humor outflow and reduce intraocular pressure. - Phentolamine Ophthalmic Solution 0.75% · Ophthalmology
Phentolamine is an alpha-adrenergic antagonist that blocks norepinephrine signaling in the eye to reduce pupil dilation and improve visual function in patients with presbyopia. - Phentolamine Opthalmic Solution 0.75% · Ophthalmology
Phentolamine is an alpha-adrenergic receptor antagonist that blocks norepinephrine signaling in the eye to reduce pupil dilation and improve aqueous humor outflow.
Phase 2 pipeline
- APX3330 · Ophthalmology
Inhibits the enzyme TGFBR2 - Phentolamine Mesylate Ophthalmic Solution 1%
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Ocuphire Pharma, Inc.
What is Ocuphire Pharma, Inc.'s pipeline?
Ocuphire Pharma, Inc. has 3 drugs in Phase 3, 2 in Phase 2, 0 in Phase 1. Late-stage candidates include Low dose pilocarpine, Phentolamine Ophthalmic Solution 0.75%, Phentolamine Opthalmic Solution 0.75%.
Related
- Sector hub: All tracked pharma companies